Live from New Orleans: Takeaways from LLY Analyst Event and Retatrutide Presentations

Research evidence excerpt

Live from New Orleans: Takeaways from LLY Analyst Event and Retatrutide Presentations

Biopharmaceuticals

Eli Lilly and Company (LLY)

EQUITY RESEARCH Company Update

June 7, 2026

Live from New Orleans: Takeaways from LLY Analyst Price: $1,131.42

Price Target: $1,230.00 Event and Retatrutide Presentations

Rating: Overweight

The second half of Saturday’s ADA was LLY-focused, highlighted by (1)

Key Statistics: retatrutide data from TRANSCEND-T2D-1 and TRIUMPH-1, and (2) LLY’s

Symbol NYSE: LLY own analyst event to close out the evening. At a high-level, we would 52-Week Range 623.78 - 1,166.29

characterize the retatrutide data updates as straightforward and clean. Market Cap 1,065,505.1

ADV (3 mo) 3,100,081 There weren’t any notable surprises that popped up in the presentation.

Shares Out (M) 941.7 Some KOLs and investors wanted more details around the heart rate

changes seen in the phase 3 after notable increases in the phase 2, though

Research Analysts: concerns seemed mostly assuaged by LLY commentary that these were

Carter Gould minor after titration. Similarly, UTIs incidence went barely remarked upon.

212-915-1794 We came away from the LLY analyst event with the notable takeaways: Carter.Gould@cantor.com

Ryan Chen ●Clear enthusiasm around eloralintide. LLY messaging on its amylin

212-294-7862 program was as upbeat and ambitious as we can remember. Multiple Ryan.Chen@cantor.com

LLY executives referenced the breadth of the clinical program,

REV ($B) emphasizing the broader potential for the program – notably not ruling

FYE Dec 2025A 2026E 2027E out potential benefits across the broader swath of cardiometabolic

1Q $12.7 $19.8E - conditions (though the outcome study will likely inform how aggressive

2Q $15.6 $20.8E - the company may be on this front).